PriceTargets.com logo

Hemostemix - HEM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$0.96
  • Forecasted Upside: 336.36%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$0.22 As of 01/27/2023 04:36 PM ET
▼ -0.03 (-12.00%)

This chart shows the closing price for HEM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hemostemix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HEM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HEM

Analyst Price Target is C$0.96
▲ +336.36% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Hemostemix in the last 3 months. The average price target is C$0.96, with a high forecast of C$0.96 and a low forecast of C$0.96. The average price target represents a 336.36% upside from the last price of C$0.22.

This chart shows the closing price for HEM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Hemostemix.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/30/2022Fundamental ResearchSet TargetBuyC$0.96
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.62 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Hemostemix logo
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Read More

Today's Range

Now: C$0.22
Low: C$0.22
High: C$0.24

50 Day Range

MA: C$0.18
Low: C$0.14
High: C$0.27

52 Week Range

Now: C$0.22
Low: C$0.12
High: C$0.42

Volume

298,144 shs

Average Volume

116,147 shs

Market Capitalization

C$16.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Hemostemix?

The following Wall Street research analysts have issued research reports on Hemostemix in the last twelve months: Fundamental Research.
View the latest analyst ratings for HEM.

What is the current price target for Hemostemix?

1 Wall Street analysts have set twelve-month price targets for Hemostemix in the last year. Their average twelve-month price target is C$0.96, suggesting a possible upside of 336.4%. Fundamental Research has the highest price target set, predicting HEM will reach C$0.96 in the next twelve months. Fundamental Research has the lowest price target set, forecasting a price of C$0.96 for Hemostemix in the next year.
View the latest price targets for HEM.

What is the current consensus analyst rating for Hemostemix?

Hemostemix currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HEM will outperform the market and that investors should add to their positions of Hemostemix.
View the latest ratings for HEM.

What other companies compete with Hemostemix?

Other companies that are similar to Hemostemix include IBEX Technologies, Liberty Biopharma, Crescita Therapeutics, Neptune Wellness Solutions and Medicure. Learn More about companies similar to Hemostemix.

How do I contact Hemostemix's investor relations team?

Hemostemix's physical mailing address is Bay 1, PO Box 10, BLACKFALDS, AB T0M 0J0, Canada. The biotechnology company's listed phone number is +1-403-3409207. The official website for Hemostemix is www.hemostemix.com. Learn More about contacing Hemostemix investor relations.